Locobase® REPAIR Used as an Adjunctive to Standard Therapy in Children With Moderate to Severe Atopic Dermatitis

• Status: Completed
• Trial end date: 2008-09-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess the efficacy of Locobase REPAIR® when used in children with moderate to severe AD

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Pharma Europe B.V.

Criteria

Inclusion Criteria:

• Has given written informed consent (parents or guardian, child if applicable)

• Moderate to severe AD

• Continuous use of topical corticosteroid or topical calcineurin inhibitor (TCI) as active treatment of AD for more than 4 weeks prior to screening (no change in topical corticosteroid or TCI is allowed between screening and day 1)

• In the opinion of the investigator, subject is unlikely to require a significant change to his/her current treatment regimen during the study period

Exclusion Criteria:

• Has infected lesions

• The last assessment of any clinical study within 3 months prior to the expected date of entering into the study

• Current use of Locobase® REPAIR

• Known allergy to Locobase® REPAIR or any of its components

• Any clinical condition which, in the opinion of the investigator, would not allow safe completion of the study